Apremilast in the Treatment of Uveitis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Uveitis
Interventions
DRUG

Apremilast

oral dose of 30 mg BID for 6 months

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Oregon Health and Science University

OTHER